Skip to content
Congress·In Committee·about 1 year ago

Congress moves to block consumer ads for newly approved drugs for 3 years, with limited waiver option

Also known as: Responsibility in Drug Advertising Act of 2025

Legislative Progress

✓ Filed
Review
House
Senate
President

Impacts

Mixed Impacts(1)
Chronic Illness
Neutral

Key Points

  • Congress would ban drug makers from advertising newly approved prescription drugs directly to the public for the first 3 years after approval, including on social media.
  • A drug company could ask for a limited waiver in the third year, but only if federal health officials decide the ads would help public health.
  • After the first 3 years, federal health officials could still block consumer ads for a drug if new safety problems show up after people start using it more widely.
  • The bill tells federal health officials to update the rules for drug ads within 1 year after the law is enacted.
  • For everyday people, this could mean fewer “ask your doctor about…” ads for new drugs, and more time for safety issues to be spotted before heavy marketing starts.
HealthcareConsumer ProtectionPrescription Drugs

Milestones

2 milestones2 actions
Feb 7, 2025House

Referred to the House Committee on Energy and Commerce.

Feb 7, 2025

Introduced in House

What Happens Next

Projected impacts based on AI analysis

Within 1 year after the bill becomes law

FDA updates its drug advertising rules to carry out the new limits

You may start seeing clearer enforcement around which prescription drugs can be advertised to the public, especially online and on social media

Starting after the bill becomes law, for drugs covered by the effective-date rule

New 3-year ad blackout starts for newly approved drugs (with a possible waiver late in year 3)

Brand-new prescription drugs would generally not be marketed directly to you through ads during their first 3 years on the market

Any time after the first 3 years, if safety evidence supports it

FDA can block ads even after year 3 if serious safety problems show up

If a drug later appears to have major harmful side effects, you might stop seeing ads for it even if it has been on the market for years

Related News

2 articles
POLITICO·6 months ago

Trump announces crackdown on pharmaceutical advertising

White House memo directs tougher enforcement of existing direct-to-consumer drug ad rules, including on social media; related policy area but not this specific 3-year post-approval ban bill.

CL~
The Wall Street Journal·9 months ago

Senators Propose Ban on Drug Advertising to Consumers

Reports on senators proposing a broad ban on direct-to-consumer drug ads and references earlier legislation to restrict ads in the first three years after FDA approval (the same concept as this bill).

CR~

Source Information

Document Type

Congressional Bill

Official Title

Responsibility in Drug Advertising Act of 2025

Bill NumberHR 1117
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the House Committee on Energy and Commerce.

Sponsor

Analysis generated by AI. While we strive for accuracy, this should not be considered legal or professional advice. Always verify information with official government sources.